Background/Objective: The preclinical stage of rheumatoid arthritis (RA) is marked by the existence of antibodies against citrullinated proteins (ACPA), subclinical arthritis, and discomfort. Years before RA manifests clinically, ACPA first appear. Imaging tests have found inflammatory and structural abnormalities in a subset of these people who have ACPA (but not yet RA). The chance of developing RA is higher in this group of patients. Interventions that target this mechanism may be effective for very early interventions, ultimately averting the onset of autoimmune inflammatory illnesses like RA, as T cell mediated B cell activation is a vital step for triggering the beginning of these conditions.
Because it prevents T cell activation and has a well-known favorable safety profile in the treatment of RA, abatacept looks to be a promising method in this endeavor.
To determine whether abatacept, in individuals with ACPA and MRI evidence of inflammation, but have not yet developed RA, may reverse subclinical arthritis as compared to placebo.
These findings indicate that abatacept dramatically reduces subclinical arthritis in people who are at high risk of developing RA. The statistics also lend support to the idea that early intervention could stop or at least delay the onset of RA.
<h3>What is
rheumatoid arthritis (RA)?</h3>
A chronic inflammatory condition, rheumatoid arthritis can harm more than just your joints. Skin, eyes, lungs, heart, and blood vessels are just a few of the physiological systems that the illness might harm in some people.
To learn more about rheumatoid arthritis with the help of given link:
brainly.com/question/1953955
#SPJ4